Anesthesia and Circulating Tumor Cells in Breast Cancer

Phase 4

Completed

• Conditions: Female Breast Carcinoma
• Interventions: Drug: Sevoflurane; Drug: Propofol

• Registration Number: NCT02005770
• Lead Sponsor: University of Zurich

Brief Summary

Serious concern about the role of anesthesia in tumor recurrence has considerably risen over years, but the lack of surrogate markers for tumor spreading made trials addressing this issue difficult to realize. In breast cancer patients CTC positivity has been recently recognized as an independent prognostic factor. In this respect, we postulated that in a first step changes in the number of CTC after general anesthesia would help to determine the effect of anesthesia on this tumor marker.

Detailed Description

Patients with primary breast cancer will be randomized to either propofol or sevoflurane anesthesia for curative surgery. CTC will be determined in the pre- as well as postoperative phase and the kinetic of CTC in the two groups will be compared.

Study Timeline

• Study First Submitted: 2013-12-03
• Study First Submitted QC: 2013-12-06
• Study First Posted: 2013-12-09
• Study Start: 2014-03
• Primary Completion: 2018-04
• Study Completion: 2018-04
• Status Verified: 2020-04
• Last Update Submitted: 2020-04-10
• Last Update Posted: 2020-04-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 221

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Sevoflurane	Sevoflurane	General anesthesia using Sevoflurane
Propofol	Propofol	General anesthesia using propofol TCI

Primary Outcome Measures

Name	Time	Method
Number of CTC before and after administration of anesthetics	5 days

Trial Locations

Locations (2)

Institute of Physicians for Anesthesia and Intensive Care Klinik Hirslanden; 🇨🇭 Zurich, Switzerland

University Hospital Zurich, Institute of Anesthesiology; 🇨🇭 Zurich, ZH, Switzerland